Cerner and Imprivata Announce Authentication Solution Compliant with DEA Requirements for e-Prescribing of Controlled Substances

Imprivata’s two-factor authentication, supported in Cerner Millennium® through Cerner’s Instant Access®, is the only solution on the market that supports all two-factor authentication modalities approved by the DEA for EPCS.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
We are proud to offer our partner Cerner an integrated solution that streamlines workflows in this new capacity, while also improving the safety and efficiency of e-prescribing of controlled substances.

New Orleans, LA (PRWEB) March 05, 2013

Cerner, a leading health care company, and Imprivata®, the leader in healthcare IT security, today announced the availability of two-factor authentication to support the prescriber validation requirements for Electronic Prescribing of Controlled Substances (EPCS) from within Cerner Millennium. Imprivata’s two-factor authentication is the only solution on the market that supports all authentication modalities allowed by the Drug Enforcement Administration (DEA), including finger biometrics, one-time password tokens and smart cards. Cerner Instant Access, embedded with Imprivata OneSign, was an integral factor in Cerner Millennium’s successful completion of the DEA’s rigorous EPCS audit process under the Interim Final Rule (IFR). This enables Cerner clients to electronically transmit prescriptions for drugs that are maintained on the DEA’s list of controlled substances.

“Electronic Prescribing for Controlled Substances is a critical step in the transformation of the health care industry from manual to automated processes,” said Chris Shaw, Senior VP and GM OneSign, Imprivata. “The breadth and depth of Imprivata’s intellectual property in the area of authentication uniquely position Imprivata OneSign to address the requirements of the DEA while offering care providers flexibility. We are proud to offer our partner Cerner an integrated solution that streamlines workflows in this new capacity, while also improving the safety and efficiency of e-prescribing of controlled substances.”

The DEA's IFR associated with electronic prescriptions for controlled substances was established in June 2010. It covers security technologies and workflow processes relevant to all software application providers, prescribers, and pharmacies involved in enabling, writing, and filling e-prescriptions for controlled substances. Health care organizations are adopting EPCS in accordance with the DEA’s IFR in order to:

  • Enhance security over controlled substances
  • Streamline workflows for care providers to enable more time focusing on patient care
  • Fulfill prescriptions for patients more quickly
  • Improve patient safety as errors associated with writing and reading prescriptions are reduced
  • Automate refill authorizations
  • Improve productivity and cost efficiency
  • Ensure important patient information about controlled substances is automatically integrated into the EHR

“With Cerner Instant Access, Cerner and Imprivata have been delivering on authentication management solutions for more than five years, enhancing authentication and access security while streamlining clinical workflows,” said John Gresham, Vice President with Cerner. “Imprivata addressed our two-factor authentication needs as we extended the capabilities of our Instant Access solution to support the e-prescribing of narcotics as required by DEA and state regulations for Cerner Millennium. Given they are the only vendor on the market that supports all authentication modalities, it was important to us that we provided that flexibility to our clients.”

About Cerner
Cerner is contributing to the systemic change of health and care delivery. For more than 30 years Cerner has been executing its vision to make healthcare safer and more efficient. We started with the foundation of digitizing paper processes and now offer the most comprehensive array of information software, professional services, medical device integration, remote hosting and employer health and wellness services. Cerner systems are used by everyone from individual consumers, to single-doctor practices, hospitals, employers and entire countries. Taking what we’ve learned over more than three decades, Cerner is building on the knowledge that is in the system to support evidence-based clinical decisions, prevent medical errors and empower patients in their care.

Cerner® solutions are licensed by approximately 10,000 facilities around the world, including more than 2,700 hospitals; 4,150 physician practices; 45,000 physicians; 550 ambulatory facilities, such as laboratories, ambulatory centers, behavioral health centers, cardiac facilities, radiology clinics and surgery centers; 800 home health facilities; 45 employer sites and 1,750 retail pharmacies.

Certain trademarks, service marks and logos (collectively, the “Marks”) set forth herein are owned by Cerner Corporation and/or its subsidiaries in the United States and certain other countries throughout the world. All other non-Cerner Marks are the property of their respective owners. Nasdaq: CERN. For more information about Cerner, please visit http://www.cerner.com, Twitter, Facebook and YouTube.

About Imprivata
Imprivata, the leader in healthcare IT security, enables secure access and collaboration for two million healthcare users worldwide. As the #1 independent provider of single sign-on and access management solutions for healthcare and other regulated industries, Imprivata OneSign® Single Sign-On is exclusively endorsed by the American Hospital Association (AHA) and recognized by Gartner and KLAS. Imprivata Cortext™ is the leading free HIPAA compliant text messaging solution for healthcare. Headquartered in Lexington, Massachusetts, Imprivata serves 1,300 hospitals in partnership with over 200 EMR and technology infrastructure vendors around the world. For more information, please visit http://www.imprivata.com.

All Imprivata products are trademarks of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn